Figure 5. DCX- and BrdU-positive cells in the SVZ and SGZ 12 weeks after depletion of neurogenesis followed dMCAO.

(A) Qualification of BrdU-immunoreactive cells in the SVZ (left panel) and SGZ (right panel) of vehicle- or GCV-treated middle-aged DCX-TK⁽⁻⁾ and DCX-TK⁽⁺⁾ mice at 12 weeks after dMCAO. *P<0.05. (B) Qualification of DCX-immunoreactive cells in the SVZ (left panel) and SGZ (right panel) of vehicle- or GCV-treated middle-aged DCX-TK⁽⁻⁾ and DCX-TK⁽⁺⁾ mice at 12 weeks after dMCAO. *P<0.05 (C) Qualification of DCX/BrdU-positive cells in the SVZ of vehicle- or GCV-treated DCX-TK⁽⁺⁾ and DCX-TK⁽⁻⁾ mice at 12 weeks after depletion of neurogenesis.